Aquestive Therapeutics (NASDAQ:AQST) Receives Buy Rating from Wedbush

Wedbush reiterated their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQST) in a report published on Monday, TipRanks reports. They currently have a $37.00 price objective on the stock.

Several other research firms have also recently weighed in on AQST. HC Wainwright reiterated a buy rating and set a $14.00 price objective (up from $12.00) on shares of Aquestive Therapeutics in a research report on Monday. Zacks Investment Research upgraded Aquestive Therapeutics from a hold rating to a buy rating and set a $6.00 target price for the company in a report on Monday, November 11th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $18.40.

Shares of NASDAQ:AQST opened at $8.74 on Monday. The firm has a 50 day simple moving average of $5.03 and a 200 day simple moving average of $4.17. Aquestive Therapeutics has a 52 week low of $2.95 and a 52 week high of $10.00. The company has a market cap of $195.09 million, a PE ratio of -3.12 and a beta of 2.70.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. California Public Employees Retirement System boosted its holdings in shares of Aquestive Therapeutics by 5.8% during the third quarter. California Public Employees Retirement System now owns 120,900 shares of the company’s stock worth $384,000 after purchasing an additional 6,600 shares during the period. Wedbush Securities Inc. increased its stake in Aquestive Therapeutics by 39.2% in the 3rd quarter. Wedbush Securities Inc. now owns 98,489 shares of the company’s stock valued at $313,000 after buying an additional 27,756 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in Aquestive Therapeutics in the 2nd quarter worth approximately $361,000. Royal Bank of Canada purchased a new stake in Aquestive Therapeutics in the 2nd quarter worth approximately $249,000. Finally, Paloma Partners Management Co purchased a new stake in Aquestive Therapeutics in the 2nd quarter worth approximately $213,000. 54.25% of the stock is owned by institutional investors and hedge funds.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.

Featured Article: Why are gap-down stocks important?

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.